p38 MAPK inhibitors: a patent review (2012 - 2013). (Q38194600)

30 August 2017

1 reference

title

p38 MAPK inhibitors: a patent review (2012 - 2013). (English)

1 reference

30 August 2017

Stefan A Laufer

2

0 references

author name string

Stefanie Bühler

series ordinal

1

1 reference

PubMed ID

24611721

30 August 2017

language of work or name

English

0 references

publication date

10 March 2014

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

1 reference

30 August 2017

24

1 reference

30 August 2017

5

1 reference

30 August 2017

535-554

1 reference

Perspective on the discovery and scientific impact of p38 MAP kinase

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Mechanisms and functions of p38 MAPK signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Novel strategies for inhibition of the p38 MAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

The primary structure of p38 gamma: a new member of p38 group of MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

"Go upstream, young man": lessons learned from the p38 saga

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Successful structure-based design of recent p38 MAP kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

A general strategy for creating "inactive-conformation" abl inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Novel triazolopyridylbenzamides as potent and selective p38α inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

Intracellular targets : current data on effectiveness and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.894977

10.1517/13543776.2014.894977

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24611721